Advertisement

Metformin

  • Xiu-Ying Yang
  • Guan-Hua DuEmail author
Chapter

Abstract

Metformin is a biguanide compound originated from the extraction of goat’s rue plants, also known as Galega officinalis. The structure of metformin was identified by British scholars in the early 1920s, and its hypoglycemic effect was found through the study of galegine in 1950s. Metformin is a first-line drug for the treatment of type 2 diabetes, mainly used as an oral hypoglycemic drug in clinical practice, especially for obese patients with normal renal function. Metformin is able to reduce the levels of blood glucose and lipid as well as capable of regulating cell growth, anti-inflammation, antiaging, etc. The main pharmacological mechanisms involve the inhibition of hepatic gluconeogenesis, activation of AMPK, and regulation of mitochondrial function. With more and more novel pharmacological effects discovered besides hypoglycemic, the application prospect of metformin would be more optimistic.

Keywords

Metformin Glucophage Diabetes Galega officinalis 

References

  1. 1.
    Werner A, Bell J. CCX1V. The preparation of methylguanidine and of ââ-dimethylguanidine by the interaction of dicyanodiamide and methylammonium and dimethylammonium chlorides respectively. J Chem Soc Trans. 1922;121:1790–4.CrossRefGoogle Scholar
  2. 2.
    Slotta KH, Tschesche R. Uber Biguanide. II. Die Blutzuckersenkende Wirkung der Biguanides. Ber Dtsch Chem Ges B: Abh. 1929;62:1398–405.CrossRefGoogle Scholar
  3. 3.
    Bailey CJ, Day C. Metformin: its botanical background. Pract Diabetes Int. 2004;21(3):115–7.CrossRefGoogle Scholar
  4. 4.
    Hall SS. A trial for the ages. Science. 2015;349(6254):1274–8.CrossRefGoogle Scholar
  5. 5.
    Madiraju AK, Erion DM, Rahimi Y, et al. Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase. Nature. 2014;510(7506):542–6.CrossRefGoogle Scholar
  6. 6.
    Geerling JJ, Boon MR, van der Zon GC, et al. Metformin lowers plasma triglycerides by promoting VLDL-triglyceride clearance by brown adipose tissue in mice. Diabetes. 2014;63(3):880–91.CrossRefGoogle Scholar
  7. 7.
    Morales DR, Morris AD. Metformin in cancer treatment and prevention. Annu Rev Med. 2015;66:17–29.CrossRefGoogle Scholar
  8. 8.
    ClinicalTrials.gov [Internet]. Identifier NCT00287391, Metformin in Longevity Study (MILES). 2015.Google Scholar
  9. 9.
    Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia. 2015;58(3):429–42.CrossRefGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. and People's Medical Publishing House, PR of China 2018

Authors and Affiliations

  1. 1.Beijing Key Laboratory of Drug Targets Identification and Drug Screening, Centre for Pharmaceutical Screening, Institute of Materia MedicaChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijingChina

Personalised recommendations